Selected Publications
Efficient and stable production of Modified Vaccinia Ankara virus in two-stage semi-continuous and in continuous stirred tank cultivation systems.
PLoS One. 2017 Aug 24;12(8):e0182553. doi: 10.1371/journal.pone.0182553. eCollection 2017. PMID: 28837572
Continuous cell lines from the Muscovy duck as potential replacement for primary cells in the production of avian vaccines.
AVIAN PATHOLOGY, 2016 VOL. 45, NO. 2, 137–155 DOI: 10.1080/03079457.2016.1138280
Impaired antiviral response of adenovirus-transformed cell lines supports virus replication.
Gen Virol. 2015 Dec 8. doi: 10.1099/jgv.0.000361. PubMed PMID: 26647282.
Purification of modified vaccinia virus Ankara from suspension cell culture.
2015. BMC Proceedings 9(Suppl 9):O13
Boosting Upstream, Downstream Processing: To Expedite Biomanufacturing, Deploy a New Genotype of Modified Vaccinia Virus Ankara.
Jordan IGEN Genetic Engineering & Biotechnology News, 2014 Jul 1 (Vol. 34, No. 13).
The avian cell line AGE1.CR.pIX characterized by metabolic flux analysis.
BMC Biotechnol. 2014 Jul 30; 14(1):72. [Epub ahead of print] PubMed PMID: 25077436.
Propagation of viruses infecting waterfowl on continuous cell lines of Muscovy duck (Cairina moschata) origin.
Avian Pathol. 2014 Jul 3; 1-28. [Epub ahead of print] PubMed PMID: 24992264.
Matrix and backstage: cellular substrates for viral vaccines
Viruses. 2014 Apr 11; 6(4):1672-700. doi: 10.3390/v6041672. PubMed PMID: 24732259; PubMed Central PMCID: PMC4014716.
High cell density cultivations by alternating tangential flow (ATF) perfusion for influenza A virus production using suspension cells.
Vaccine. 2014 Feb 25; pii: S0264-410X(14)00189-3. doi: 10.1016/j.vaccine.2014.02.016. [Epub ahead of print] PubMed PMID: 24583003
Pharmaceutical Cell Lines for Biologics Production: Manipulation of cell growth, metabolism and product quality attributes
2014, Pages: 216-246, DOI (Chapter): https://doi.org/10.1515/9783110278965.216
Elements in the Development of a Production Process for Modified Vaccinia Virus Ankara
Microorganisms 2013, 1, 100–121.
Continuous influenza virus production in cell culture shows a periodic accumulation of defective interfering particles.
PLoS One. 2013 Sep 5; 8(9):e72288. doi: 10.1371/journal.pone.0072288. eCollection 2013. PubMed PMID: 24039749; PubMed Central PMCID: PMC3764112.
A novel genotype of MVA that efficiently replicates in single cell suspensions.
BMC Proceedings 2013, 7(Suppl 6):O1. doi:10.1186/1753-6561-7-S6-O1.
A genotype of modified vaccinia Ankara (MVA) that facilitates replication in suspension cultures in chemically defined medium.
Viruses. 2013 Jan 21; 5(1):321-39. doi: 10.3390/v5010321. PubMed PMID: 23337383; PubMed Central PMCID: PMC3564123
Live attenuated influenza viruses produced in a suspension process with avian AGE1.CR.pIX cells.
BMC Biotechnol. 2012 Oct 30; 12:79. doi: 10.1186/1472-6750-12-79. PubMed PMID: 23110398; PubMed Central PMCID: PMC3505166.
Production of a Viral-Vectored Vaccine Candidate Against Tuberculosis.
BioProcess International; Sep 2012
A chemically defined production process for highly attenuated poxviruses.
Biologicals. 2011 Jan; 39(1): 50–8. Epub 2011 Jan 15.
PMID: 21237672
New avian suspension cell lines provide production of influenza virus and MVA in serum-free media: studies on growth, metabolism and virus propagation.
Vaccine. 2009 Aug 6; 27(36): 4975-82. Epub 2009 Jun 14.
PMID: 19531390 [PubMed – indexed for MEDLINE]
An avian cell line designed for production of highly attenuated viruses.
Vaccine 27(5): 748–56
Glycan analysis in cell culture-based influenza vaccine production: influence of host cell line and virus strain on the glycosylation pattern of viral hemagglutinin.
Vaccine. 2009 Jul 9; 27(32): 4325-36. Epub 2009 May 14.
PMID: 19410619 [PubMed – indexed for MEDLINE]
An avian cell line designed for production of highly attenuated viruses.
Vaccine. 2009, Jan 29; 27(5): 748–56. Epub 2008 Dec 9.
PMID: 19071186 [PubMed – indexed for MEDLINE]
An Avian Designer Cell Line for Vaccine Manufacture.
BioWorld Europe. 03–2007
CD26/DPP4 cell-surface expression in bat cells correlates with bat cell susceptibility to Middle East respiratory syndrome coronavirus (MERS-CoV) infection and evolution of persistent infection.
PLos One. 2014 Nov 19; 9(11):e112060. doi: 10.1371/journal.pone.0112060. eCollection 2014; PMID: 25409519
Influenza A Virus Polymerase Is a Site for Adaptive Changes During Experimental Evolution in Bat Cells.
J Virol. 2014 Aug 20; pii: JVI.01857-14. [Epub ahead of print] PubMed PMID: 25142579
Establishment of fruit bat cells (Rousettus aegyptiacus) as a model system for the investigation of filoviral infection.
PLoS Negl Trop Dis. 2010 Aug 24; 4(8): e802.
PMID: 20808767 [PubMed - indexed for MEDLINE] Free PMC Article
Cell lines from the Egyptian fruit bat are permissive for modified vaccinia Ankara.
Virus Res. 2009 Oct; 145(1): 54-62. Epub 2009 Jun 18.
PMID: 19540275 [PubMed - indexed for MEDLINE]
The influence of cell growth and enzyme activity changes on intracellular metabolite dynamics in AGE1.HN.AAT cells.
J Biotechnol. 2014 May 20; 178:43-53. doi: 10.1016/j.jbiotec.2014.03.012. Epub 2014 Mar 18. PMID: 24657347
N-glycosylation and biological activity of recombinant human alpha1-antitrypsin expressed in a novel human neuronal cell line.
Biotechnology and Bioengineering, Volume 108, Issue 9, pages 2118-2128, September 2011
Quercetin treatment changes fluxes in the primary metabolism and increases culture longevity and recombinant α1-antitrypsin production in human AGE1.HN cells.
Appl Microbiol Biotechnol 2011 (11) 3811-3814 DOI 10.1007/s00253-011-3811-4
Quantitative characterization of metabolism and metabolic shifts during growth of the new human cell line AGE1.HN using time resolved metabolic flux analysis
Bioprocess Biosyst Eng. 2010 Dec 25. [Epub ahead of print]
PMID: 21188421 [PubMed - as supplied by publisher]
Towards a 21st-century roadmap for biomedical research and drug discovery: consensus report and recommendations.
Article in Drug discovery today · October 2016, DOI: 10.1016/j.drudis.2016.10.011
Biology-inspired microphysiological system approaches to solve the prediction dilemma of substance testing.
ALTEX. 2016; 33:272–321. doi: 10.14573/altex.1603161
Modeling Human Immunity In Vitro: Improving Artificial Lymph Node Physiology by Stromal Cells
Applied In Vitro Toxicology. September 2016 2(3): 143-150. doi:10.1089/aivt.2016.0004.
Human immunity in vitro - Solving immunogenicity and more.
ADDR 2014 Apr; 69-70:103-122
Crosstalk between immune cells and mesenchymal stromal cells in a 3D bioreactor system.
Int J Artif Organs 2012; 35: (11) 986-995
Engineering tissue alternatives to animals: applying tissue engineering to basic research and safety testing.
Regen. Med. 2010, 4(4), 579–592
Immunological substance testing on human lymphatic micro-organoids in vitro.
Journal of Biotechnology 2010, Volume 148, Issue 1, 1 July 2010, Pages 38–45
A Human Lymph Node In Vitro – Challenges and Progress
Journal of Artificial Organs. 2006, 30(10):803–808
Increasing antibody yield and modulating final product quality using the FreedomTM CHO-STM production platform.
BMC Proceedings 2011, 5(Suppl 8):P102 http://www.biomedcentral.com/1753-6561/5/S8/P102
Alternative Strategies and New Cell Lines for High-level Production of Biopharmaceuticals
In: Knäblein: Modern Biopharmaceuticals, Wiley-VCH. 2005. 761-778
Mammalian cells
In: G. Gelissen: Production of recombinant proteins. Wiley-VCH. 2005. 233-252
A novel bicistronic gene design couples stable cell line selection with a fucose switch in a designer CHO host to produce native and afucosylated glycoform antibodies.
MAbs. 2018 Feb 22:1-15. doi: 10.1080/19420862.2018.1433975. [Epub ahead of print]
Engineering of CHO Cells for the Production of Recombinant Glycoprotein Vaccines with Xylosylated N-glycans.
Bioengineering (Basel). 2017 Apr 28;4(2). pii: E38. doi: 10.3390/bioengineering4020038. PMID:28952517
Fucose-targeted glycoengineering of pharmaceutical cell lines.
Methods Mol Biol. 2012; 907:507-17 PMID: 22907371
Production of non-fucosylated antibodies by co-expression of heterologous GDP-6-deoxy-D-lyxo-4-hexulose reductase.
Glycobiology. 2010 Dec; 20 (12):1607-18. PMID: 20639190
Characterization of Recombinant Proteins (Chapter 9.)
DOI: 10.1002/9783527632909.ch9 in Kayser and Warzecha (Eds.) (2012): Pharmaceutical Biotechnology: Drug Discovery and Clinical Applications
Quantitative MALDI-TOF-MS Using Stable-isotope Labeling: Application to the Analysis of N-glycans of Recombinant α-1 Antitrypsin Produced Using Different Culture Parameters.
Journal of Carbohydrate Chemistry, 30:320–333, 2011 DOI: 10.1080/07328303.2011.605194
Quality for Biologics.
Biopharm Knowledge Publishing. 2008
Standardization, evaluation and early-phase method validation of an analytical scheme for batch-consistency N-glycosylation analysis of recombinant produced glycoproteins.
European Journal of Pharmaceutics and Biopharmaceutics. 2008, 68: 818–827, DOI: 10.1016/j.ejpb.2007.08.015
Drug Testing In Vitro – Breakthroughs and Trends in Cell Culture Technology.
Wiley-VCH Verlag GmbH & Co. KgaA. 2007
Development and Assessment of Human Adenovirus Type 11 as a Gene Transfer Vector.
Journal of Virology. 2005. April. 5090-5104, DOI: 10.1128/JVI.79.8.5090-5104.2005
Genome Size and Structure Determine Efficiency of Postinternalizytion Steps and Gene Transfer of Capsid-Modified Adenovirus Vectors in a Cell-Type-Specific Manner.
Journal of Virology. 2004 Sept, 10009–10022, doi: 10.1128/JVI.78.18.10009-10022.2004
The complete nucleotide sequence, genome organization, and orign of human adenovirus type11.
Virology. 2003 Apr 25. 309(1): 152–165, DOI: 10.1016/S0042-6822(02)00085-5
State-of-the-Art and New Optionsto Assess T Cell Activation by Skin Sensitizers: Cosmetics Europe Workshop
ALTEX 35(2), 2018
Novel Bioreactors for Fragile Glycoproteins.
GEN. 2007, January (Vol. 27, No. 1) 1: 34–35